Neurocrine Biosciences Inc. Earnings

Neurocrine Biosciences Inc.’s revenue jumped 11.12% since last year same period to $572.6Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -8.78% fall in its revenue since last 3-months.

Neurocrine Biosciences Inc.’s net profit fell -81.8% since last year same period to $7.9Mn in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -92.34% fall in its net profits since last 3-months.

Neurocrine Biosciences Inc.’s net profit margin fell -83.62% since last year same period to 1.38% in the Q1 2025. On a quarterly growth basis, Neurocrine Biosciences Inc. has generated -91.6% fall in its net profit margins since last 3-months.

Neurocrine Biosciences Inc.’s price-to-earnings ratio after this Q1 2025 earnings stands at 43.92.

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current quarter stand at 0.98 - a -10.57% fall from last quarter’s estimates.

Neurocrine Biosciences Inc.’s earning per share (EPS) estimates for the current year stand at 0.98.

Neurocrine Biosciences Inc.’s earning per share (EPS) jumped 66.67% since last year same period to 0.7 in the Q1 2025. This indicates that the Neurocrine Biosciences Inc. has generated 66.67% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Neurocrine Biosciences Inc.’s return on assets (ROA) stands at 0.09.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Neurocrine Biosciences Inc.’s return on equity (ROE) stands at 0.12.